Progression in therapy of erlotinib for patients with non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 12, Issue 12, 2009, Pages 1352-1355

  Meng, Fanlu ^a   Ma, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY;

EID: 75449097417     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.12.26     Document Type: Short Survey

References (22)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med, 2005, 353(2): 123-132.
2. Tiseo M, Gridelli C, Cascinu S, et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer, 2009, 64(2): 199-206.
3. Zhou CC. Hopes and the challenges of the therapy of Advanced non-small cell lung cancer. http://www.131.org.cn/article/show.php?itemid=72901.
4. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 2007, 25(12): 1545-1552.
5. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(25): 5892-5899.
6. Hightower M. A selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer, 2003, 4(6): 336-338.
7. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 2007, 25(12): 1545-1552.
8. Zhou CC. Erlotinib ASCO2009. http://www.131.org.cn/article/show. php?itemid=72768.
9. Uhm JE, Park BB, Ahn MJ, et al. Erlotinib monotherapy for stage IIIb/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol, 2009, 4(9): 1136-1143.
10. Gridelli C, Butts C, Ciardiello F, et al. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer, 2008, 9(4): 235-238.
11. Boughton B. New SATURN results show survival benefit from erlotinib in NSCLC. 13th World Conference on Lung Cancer (WCLC): Abstract A2.1. Presented August 1, 2009.
12. Han BH. Reiew of studies in lung cancer from Asco 2009 Physicians 2009. 6.
13. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebocontrolled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 27: 18s, 2009(suppl): abstr LBA8002.
14. Lee JS, Ignacio J, Yu C, et al. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol, 2008,26(suppl): abstr 8031.
15. Schwer AL, Gaspar LE. Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer, 2006, 8(3): 180-186.
16. Barnes EA, Chow E, Tsao MN, et al. Physician expectations of treatment outcomes for patients with brain metastases referred for whole brain radiotherapy. Int J Radiat Oncol Biol Phys, 2009. [Epub ahead of print].
17. von Pawel J, Wagner H, Duell T, et al. Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. Epu, 2008, 31(3): 123-126.
18. Katayama T, Shimizu J, Onozato R. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. Thorac oncol, 2009, 4(11): 1415-1419.
19. Lind JS, Lagerwaard FJ, Smit EF, et al. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cance. Int J Radiat Oncol Biol Phys, 2009, 74(5): 1391-1396.
20. Costa DB, Nguyen KS, Cho BC. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res, 2008, 14(21): 7060-7067.
21. Zhou ZT, Xu XH, Wei Q, et al. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol, 2009, 64(6): 1123-1127.
22. Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer, 2009. [Epub ahead of print].